Hims & Hers shifts business model after Novo deal

Hims & Hers (HIMS) has taken a beating, with the stock down roughly 70% from its $70 peak and now trading below $21 per share. But the story's changing. After the company's Novo Nordisk (NVO) deal and the end of the FDA shortage, Hims is shifting to a broader mix of branded, FDA-approved GLP-1s while pulling back from compounded supply. This is a shift in how the business operates. The question now is whether HIMS can build a profitable, durable model. In simple terms, Hims & Hers is an online health ...